2025-02-01 2026-01-31 2026-01-31 false 15427889 Medicsol Limited 86210General medical practice activities iso4217:GBP xbrli:pure 154278892025-02-01 154278892026-01-31 154278892025-02-01 2026-01-31 15427889bus:SmallEntities2025-02-01 2026-01-31 15427889bus:AuditExempt-NoAccountantsReport2025-02-01 2026-01-31 15427889bus:FullAccounts2025-02-01 2026-01-31 15427889core:WithinOneYear2026-01-31 15427889core:AfterOneYear2026-01-31 15427889core:WithinOneYear2025-02-01 2026-01-31 15427889core:AfterOneYear2025-02-01 2026-01-31 15427889core:CurrentFinancialInstruments2026-01-31 15427889core:Non-currentFinancialInstruments2026-01-31 15427889core:CurrentFinancialInstruments2025-02-01 2026-01-31 15427889core:Non-currentFinancialInstruments2025-02-01 2026-01-31 15427889core:LandBuildings2025-02-01 2026-01-31 15427889core:FurnitureFittings2025-02-01 2026-01-31 15427889core:OfficeEquipment2025-02-01 2026-01-31 15427889core:Vehicles2025-02-01 2026-01-31 15427889core:PlantMachinery2025-02-01 2026-01-31 15427889core:OtherPropertyPlantEquipment2025-02-01 2026-01-31 15427889core:LandBuildings2026-01-31 15427889core:PlantMachinery2026-01-31 15427889core:Vehicles2026-01-31 15427889core:FurnitureFittings2026-01-31 15427889core:OfficeEquipment2026-01-31 15427889core:OtherPropertyPlantEquipment2026-01-31 15427889core:Right-of-useAssets2025-02-01 2026-01-31 15427889core:Right-of-useAssets2026-01-31 15427889core:Goodwill2025-02-01 2026-01-31 15427889core:PatentsTrademarksLicencesConcessionsSimilar2025-02-01 2026-01-31 15427889core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-02-01 2026-01-31 15427889core:OtherResidualIntangibleAssets2025-02-01 2026-01-31 15427889core:Goodwill2026-01-31 15427889core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-01-31 15427889core:PatentsTrademarksLicencesConcessionsSimilar2026-01-31 15427889core:OtherResidualIntangibleAssets2026-01-31 15427889dpl:CostSales2025-02-01 2026-01-31 15427889dpl:AdministrativeExpenses2025-02-01 2026-01-31 15427889dpl:DistributionCosts2025-02-01 2026-01-3115427889core:ShareCapital2026-01-31 15427889core:SharePremium2026-01-31 15427889core:RevaluationReserve2026-01-31 15427889core:OtherReservesSubtotal2026-01-31 15427889core:ShareCapitalPreferenceShares2026-01-31 15427889core:CapitalRedemptionReserve2026-01-31 15427889core:OtherCapitalReserve2026-01-31 15427889core:RetainedEarningsAccumulatedLosses2026-01-3115427889core:ShareCapital2025-02-01 2026-01-31 15427889core:SharePremium2025-02-01 2026-01-31 15427889core:RevaluationReserve2025-02-01 2026-01-31 15427889core:OtherReservesSubtotal2025-02-01 2026-01-31 15427889core:RetainedEarningsAccumulatedLosses2025-02-01 2026-01-311542788912025-02-01 2026-01-31 1542788922025-02-01 2026-01-3115427889core:ShareCapital12025-02-01 2026-01-31 15427889core:ShareCapital22025-02-01 2026-01-3115427889core:SharePremium12025-02-01 2026-01-31 15427889core:SharePremium22025-02-01 2026-01-3115427889core:RevaluationReserve12025-02-01 2026-01-31 15427889core:RevaluationReserve22025-02-01 2026-01-3115427889core:RetainedEarningsAccumulatedLosses12025-02-01 2026-01-31 15427889core:RetainedEarningsAccumulatedLosses22025-02-01 2026-01-311542788912025-02-01 2026-01-3115427889core:Non-currentFinancialInstrumentscore:CostValuation2025-02-01 15427889core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-01-3115427889core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:CostValuation2026-01-3115427889core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-02-01 15427889core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-01-31 15427889core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-01-31 15427889core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-01-3115427889core:Non-currentFinancialInstruments2026-01-31 15427889core:Non-currentFinancialInstruments2025-01-31154278892024-01-19 154278892025-01-31 154278892024-01-19 2025-01-31 15427889core:WithinOneYear2025-01-31 15427889core:AfterOneYear2025-01-31 15427889core:CurrentFinancialInstruments2025-01-31 15427889core:Non-currentFinancialInstruments2025-01-31 15427889core:LandBuildings2025-01-31 15427889core:PlantMachinery2025-01-31 15427889core:Vehicles2025-01-31 15427889core:FurnitureFittings2025-01-31 15427889core:OfficeEquipment2025-01-31 15427889core:OtherPropertyPlantEquipment2025-01-31 15427889core:Right-of-useAssets2025-01-31 15427889core:Goodwill2025-01-31 15427889core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-31 15427889core:PatentsTrademarksLicencesConcessionsSimilar2025-01-31 15427889core:OtherResidualIntangibleAssets2025-01-31 15427889dpl:AdministrativeExpenses2024-01-19 2025-01-3115427889core:ShareCapital2025-01-31 15427889core:SharePremium2025-01-31 15427889core:RevaluationReserve2025-01-31 15427889core:OtherReservesSubtotal2025-01-31 15427889core:ShareCapitalPreferenceShares2025-01-31 15427889core:CapitalRedemptionReserve2025-01-31 15427889core:OtherCapitalReserve2025-01-31 15427889core:RetainedEarningsAccumulatedLosses2025-01-3115427889core:RetainedEarningsAccumulatedLosses2024-01-19 15427889core:ShareCapital2024-01-19 15427889core:SharePremium2024-01-19 15427889core:RevaluationReserve2024-01-19 15427889core:ShareCapital2024-01-19 2025-01-31 15427889core:SharePremium2024-01-19 2025-01-31 15427889core:RevaluationReserve2024-01-19 2025-01-31 15427889core:OtherReservesSubtotal2024-01-19 2025-01-31 15427889core:RetainedEarningsAccumulatedLosses2024-01-19 2025-01-311542788912024-01-19 2025-01-31 1542788922024-01-19 2025-01-3115427889core:ShareCapital12024-01-19 2025-01-31 15427889core:ShareCapital22024-01-19 2025-01-3115427889core:SharePremium12024-01-19 2025-01-31 15427889core:SharePremium22024-01-19 2025-01-3115427889core:RevaluationReserve12024-01-19 2025-01-31 15427889core:RevaluationReserve22024-01-19 2025-01-3115427889core:RetainedEarningsAccumulatedLosses12024-01-19 2025-01-31 15427889core:RetainedEarningsAccumulatedLosses22024-01-19 2025-01-3115427889bus:Director12025-02-01 2026-01-3115427889bus:Director22025-02-01 2026-01-3115427889bus:PrivateLimitedCompanyLtd2025-02-01 2026-01-31
Medicsol Limited
Unaudited Financial Statements
for the year ended 31 January 2026
Company registration number 15427889
(England and Wales)

Company Information

For the year ended 31 January 2026
Directors Hassan, Nida, Dr
Zafar, Hassan Wasim

Registered office Broadway House
9-10 Upper Clifton Street
Cardiff
CF24 1PU

Registered number 15427889

Accountant SNK Associates
Broadway House
9-10 Upper Clifton Street
Cardiff
CF24 1PU

Statement of Financial Position

As at 31 January 2026
2026
2025
£
£
£
£
Current assets
Debtors
600
-
600
-
Creditors
Amounts falling due within one year
(396)
-
(396)
-
Net current assets (liabilities)
204
-
Total assets less current liabilities
204
-
Net assets (liabilities)
204
-
Capital and reserves
Called up share capital
100
-
Profit and loss account
104
-
Total equity
204
-

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 21 October 2026 and are signed on its behalf by:

Hassan, Nida, Dr
Hassan, Nida, Dr
Director
Zafar, Hassan Wasim
Zafar, Hassan Wasim
Director

Company registration number 15427889

Notes to the Financial Statements

For the year ended 31 January 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

3. Employees

The average number of employees during the year was 0 (2025: 0).